DESIGNER BABY FIRMS SHUT DOWN EMBRYO EDITING WORK
INDUSTRY DESK■ 1 MIN READ
SAT, APR 25, 2026■ AI-SUMMARIZED FROM 1 SOURCE ▸ TIMELINE
Bootstrap Bio and Manhattan Genomics, two companies focused on human embryo editing to prevent genetic diseases, have ceased operations. The closures mark a setback for the controversial field of germline editing.
Bootstrap Bio and Manhattan Genomics have both shut down their operations, ending their respective efforts to develop human embryo editing technologies. The companies were among a small number of firms pursuing germline editing—modifications to embryos that would be inherited by future generations—primarily to prevent serious genetic conditions.
The reasons behind the closures were not immediately detailed, but the exits underscore the commercial and regulatory challenges facing the embryo editing sector. The field has faced intense scrutiny from bioethicists, policymakers, and the public since Chinese scientist He Jiankui's 2018 announcement of the first gene-edited babies, which triggered global controversy and criminal charges against him.
The U.S. and many other countries have restricted or banned germline editing in humans. While some researchers continue work on somatic gene therapy—editing non-reproductive cells—the commercial viability of human embryo editing remains highly uncertain.
■ SOURCES
► Wired■ SUMMARY WRITTEN BY AI FROM THE LINKS ABOVE
■ MORE FROM THE STARTUPS DESK
Triomics, an AI platform automating data-heavy tasks for oncologists, secured $22M in Series B funding. The raise follows a $15M Series A in 2024.
YESTERDAY— AI Desk
Xcena secured $135 million in Series B funding at a $570 million valuation for its MX1 chip, which handles data orchestration and KV cache management directly within memory modules.
YESTERDAY— AI Desk
Pittsburgh-based Gray Swan, which stress-tests AI models for frontier labs, secured $40M in Series A funding at a $200M valuation. The round was co-led by Wing VC and Madrona.
YESTERDAY— AI Desk
H1, a healthcare SaaS startup, secured $40 million in funding from CVS Health. The investment signals continued investor confidence in specialized software platforms despite AI disruption concerns.
YESTERDAY— Industry Desk